Veröffentlichungsdatum: 8 Oktober 2010
Projektträger – zwischengeschaltetes Finanzinstitut
Novozymes A/S
Ort
Beschreibung
The project concerns the European-based part of the promoter’s corporate RDI programme in the period 2010-2011 related to discovery and development of innovative enzymes, novel pharmaceutical proteins, and micro-organisms.
Ziele
The R&D investments focus on improving current products and processes as well as developing new business opportunities. The project is expected to safeguard and enhance the leading competitive position of an EU knowledge-based, R&D-driven enterprise
Sektor(en)
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 60 million.
Gesamtkosten (voraussichtlicher Betrag)
EUR 240 million.
Umweltaspekte
The project concerns investment in research and development activities that are expected to be carried out in existing R&D facilities, in which case an EIA should not be required according to Directive 85/337/EC and its amending Directives. However the promoter will be required to ensure that the provisions of the EIA Directive and those of any other relevant environmental acquis are complied with. Full environmental details will be assessed during the appraisal.
Auftragsvergabe
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. The promoter has sound procedures for procuring specialized equipment and external services and the R&D activities are carried out by internal research staff hence they are expected to be entirely appropriate to the industry and satisfactory to the Bank.
Projektstatus
Unterzeichnet - 10/12/2010
Haftungsausschluss
Bis Finanzierungen vom Verwaltungsrat genehmigt und anschließend unterzeichnet werden, befinden sich die Projekte in der Prüfungs- oder Verhandlungsphase. Die Angaben auf dieser Seite sind daher unverbindlich.
Sie dienen lediglich der Transparenz und stellen nicht die offizielle EIB-Politik dar (vgl. auch die erklärenden Anmerkungen).